secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001356576-25-000053
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q2 2025: Qelbree +31%, Sage acquisition closed, guidance raised
------------------------------------------------------------------------

- Total revenues Q2 2025: $165.5M vs $168.3M; non-GAAP rev ex-Trokendi/Oxtellar up 17% YoY.
- Qelbree net sales $77.6M (+31% YoY); GOCOVRI net sales $36.7M (+16% YoY); 225k IQVIA prescriptions.
- Adjusted operating earnings (non-GAAP) $40.9M; operating income $12.1M; raising FY 2025 guidance.
- Closed Sage Therapeutics acquisition on July 31, adding ZURZUVAE; ONAPGO launch: 750+ enrollment forms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000053/0001356576-25-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000053/supn-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001356576-25-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer